Antonín Holý
Antonín Holý (born September 1, 1936 in Prague ; † July 16, 2012 ) was a Czech natural scientist and chemist . He specialized in virus research and is considered to be the discoverer of the active ingredient tenofovir , which, as a mono ("Viread") and combined preparation ("Truvada"), has become the most important drug in HIV treatment and prophylaxis.
Life
Antonín Holý studied organic chemistry from 1954 to 1959. From 1960 he worked and researched at the Institute of Organic Chemistry and Biochemistry (IOBC) of the Czechoslovak Academy of Sciences . From around 1967 he was one of the institute's leading scientists. In 1987 he finally became head of the nucleic acid chemistry department and headed the IOBC from 1994 to 2002. It was not until 2011 that he fully retired. Antonín Holý died on July 16, 2012. On the same day, the US FDA approved the drug "Truvada" for HIV prevention.
research
Holý concentrated his research on the development of active substances for the treatment of viral infections. From 1976 onwards he worked closely with the Belgian biomedical engineer Erik de Clercq . Together they developed the antiviral drug tenofovir against hepatitis B.
From the beginning of the 1990s, Holý and de Clercq worked with the US pharmaceutical company Gilead Sciences . In 2006, his institute and the company founded a research center for the development of new active ingredients. In return, the company pledged to donate US $ 1.1 million to support research over the next five years. Several active ingredients resulted from this collaboration, including tenofovir and emtricitabine . The Gilead Group then brought the drugs based on this to market maturity.
Awards
- 1984 State Prize for Chemistry
- 1998 Hanuš Medal of the Czech Chemical Society
- 1999 honorary doctorate from Palacký University in Olomouc
- 2001 Descartes Prize of the European Union
- 2002 Medal of Merit of the Czech Republic (Za zásluhy) 1st degree
- 2003 Honorary membership of the Rega Institute for Medical Research, Catholic University of Leuven, Belgium
- 2004 honorary citizen of Prague
- 2004 Praemium Bohemiae; Medal of the Czech Academy of Sciences: De scientia et humanitate optime meritis
- 2005 Honorary Doctorate from the University of Ghent (Belgium); Medal of Merit of the Faculty of Science at Charles University in Prague
- 2006 Member of the European Academy of Sciences and Arts (Salzburg)
- 2007 State Prize Česká hlava (Czech head)
Individual evidence
- ↑ a b apotheke-adhoc.de: discoverer of Truvada has passed away ( memento from July 19, 2012 in the Internet Archive )
- ↑ Deutsches Ärzteblatt: USA: Truvada approved for HIV prevention
- ↑ welt.de: Co-discoverer of HIV prevention agent "Truvada" died
- ^ Gilead Sciences and the Institute of Organic Chemistry and Biochemistry (IOCB) Establish New Academic Research Center in Prague; Donation by Gilead Honors Leadership of Dr. Antonin Holy in Antiviral Drug Discovery and Development ( Memento of the original from February 1, 2016 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. , Gilead, July 13, 2016
- ↑ a b c IOCB: Hall of Fame / Antonín Holý
- ↑ Školní statistická ročenka 2008 . Cesky statisticky urad, 2008, ISBN 978-80-250-1728-9 , p. 154 ( limited preview in Google Book search).
| personal data | |
|---|---|
| SURNAME | Holý, Antonín |
| BRIEF DESCRIPTION | Czech natural scientist and chemist |
| DATE OF BIRTH | September 1, 1936 |
| PLACE OF BIRTH | Prague |
| DATE OF DEATH | July 16, 2012 |